Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD

Size: px
Start display at page:

Download "Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD"

Transcription

1 & 2013 International Society of Nephrology Ethnic differences in bone and mineral metabolism in healthy people and patients with CKD Vanda Jorgetti 1, Luciene M. dos Reis 1 and Susan M. Ott 2 1 Nephrology Division, Medical School, University of São Paulo, São Paulo, Brazil and 2 Department of Medicine, University of Washington, Seattle, Washington DC, USA Several studies have shown racial differences in the regulation of mineral metabolism, in the acquisition of bone mass and structure of individuals. In this review, we examine ethnic differences in bone and mineral metabolism in normal individuals and in patients with chronic kidney disease. Black individuals have lower urinary excretion and increased intestinal calcium absorption, reduced levels of 25(OH)D, and high levels of 1.25(OH) 2 D and parathyroid hormone (PTH). Body phosphorus concentration is higher and the levels of FGF-23 are lower than in whites. Mineral density and bone architecture are better in black individuals. These differences translate into advantages for blacks who have stronger bones, less risk of fractures, and less cardiovascular calcification. In the United States of America, the prevalence of kidney disease is similar in different ethnic groups. However, black individuals progress more quickly to advanced stages of kidney disease than whites. This faster progression does not translate into increased mortality, higher in whites, especially in the first year of dialysis. Some ethnicity-related variations in mineral metabolism persist when individuals develop CKD. Therefore, black patients have lower serum calcium concentrations, less hyperphosphatemia, low levels of 25(OH)D, higher levels of PTH, and low levels of FGF-23 compared with white patients. Bone biopsy studies show that blacks have greater bone volume. The rate of fractures and cardiovascular diseases are also less frequent. Further studies are required to better understand the cellular and molecular bases of these racial differences in bone mineral metabolism and thus better treat patients. Kidney International (2013) 85, ; doi: /ki ; published online 18 December 2013 KEYWORDS: bone histomorphometry; bone mineral density; chronic kidney disease; ethnic differences; mineral metabolism; vascular calcification Correspondence: Vanda Jorgetti, Faculdade de Medicina da Universidade de São Paulo, LIM 16 Laboratório de Fisiopatologia Renal, Av Dr Arnaldo, 455, 31 andar, sala nr 3342, Cerqueira César, São Paulo CEP: , Brazil. vandajor@usp.br Received 21 June 2013; revised 7 August 2013; accepted 15 August 2013; published online 18 December 2013 The risk of osteoporosis and fractures is different in various populations. 1 Individuals of African descent have higher bone density and fewer fractures than Caucasians, whereas Asians have lower fracture rates despite lower bone density. Ethnic variations are found in mineral metabolism, Ca homeostasis, serum concentrations of 25(OH)D and parathyroid hormone (PTH), as well as in acquisition of bone mass and structure These differences in bone metabolism may also be related to the differences seen in the frequency and severity of vascular calcifications (VCs). 11 The analysis of US databases has revealed that although the prevalence of early stages of chronic kidney disease (CKD) is similar in different ethnic groups, black individuals progress to advanced stages of the disease four times faster than do Caucasians. 12 In a large health-care program, blacks had more extreme rates of renal function decline, and Asians progressed more slowly than the other groups. 13 However, once on dialysis, black patients have lower mortality rates In this review, we examine ethnic differences in bone and mineral metabolism in normal individuals. As kidney disease progresses, patients develop CKD-MBD (mineral and bone disorder) that can be described by abnormalities in serum laboratory measures, bone disease, and VCs, 18 which all vary according to race. ETHNIC DIFFERENCES IN LABORATORY MEASUREMENTS OF MINERAL METABOLISM IN HEALTHY INDIVIDUALS The intake of Ca varies among different ethnic groups, some populations consuming between 300 and 400 mg/day, and others consuming three times these values. 19 Studies on calcium metabolic balance and kinetics have shown that African Americans ingest less Ca, have a more efficient intestinal absorption, and lower urinary excretion than whites. 6 Similar differences have also been observed between South African blacks and whites. 20 Braun et al. 6 compared Ca intake and retention in white and black American adolescents and found that black teenagers retained more Ca in their skeleton (mean difference of 185±32 mg Ca/day). For any amount of Ca intake, they excreted less Ca in the urine. Mechanisms involved in lower Ca urinary excretion in blacks are not yet fully known. In this study, the serum PTH and 25(OH)D Kidney International (2014) 85,

2 V Jorgetti et al.: Ethnic differences in mineral metabolism levels did not explain the urine calcium results. 6 Na et al. 21 demonstrated the existence of two black-specific variants in the gene encoding the renal epithelial channel TRPV 5 (A563T), a key protein in the regulation of renal tubular Ca handling. This variant, which is relatively common in blacks, might help to explain the lower urinary Ca excretion in these individuals. Another study evaluating Ca-sensing receptor polymorphism in blacks showed that the alleles associated with elevated blood pressure were associated with a decrease in urinary Ca excretion. 22 Few studies have assessed ethnic differences in the metabolism of phosphate (Pi). Arunabh et al. 23 used delayed gamma neutron activation and studied total body Pi in 90 black females and 143 white females ranging in age from 20 to 70 years. Results showed that total body Pi was lower in whites (401±58 vs. 448 ±58 g) even after correction for body mass index. Total body Pi decreases with age, but the differences between black and white females remain over time. Gutiérrez et al. 24 reported that blacks had a fractional excretion of Pi lower than that of whites, with similar serum PTH and fibroblast growth factor 23 (FGF23) serum levels. The results may have been altered by pre-treatment of black patients with high doses of vitamin D. The serum concentration of 25(OH)D is consistently lower in blacks and hispanics than in whites, even after adjusting for age, gender, body mass index, intake of Ca, serum Ca and serum albumin. 25 This is related to greater skin pigmentation that inhibits cutaneous synthesis of cholecalciferol. 26 After an oral dose of vitamin D, blacks increase the serum levels to the same extent as whites. 27 Serum concentrations of PTH and 1,25(OH) 2 D are higher in blacks. 28 In a multi-ethnic study from the United States, Chinese subjects had lower PTH than white, black, or Hispanic subjects. 29 Serum 25(OH)D concentrations 420 ng/ml are not associated with further suppression of PTH in blacks, in contrast to what is observed in whites or Mexican-Americans. 25 In Japan, PTH levels are lower than in Western countries, and there was no correlation between PTH and 25(OH)D when the concentrations were 437 nmol/l. 30 Fuleihan et al. 10 studied the sigmoidal Ca-PTH curve in the two ethnic groups and demonstrated that the maximum and minimum PTH response to hypocalcemia and hypercalcemia were higher in blacks, with no change in set point or slope of the curve. Autopsy findings revealed heavier parathyroid glands with higher cell numbers. 31 The higher serum levels of 1,25(OH) 2 D in black people probably contribute to higher intestinal Ca absorption than in white people. 6 In some studies, serum FGF23 concentrations do not appear to differ between normal black and white people 32,33 or between races in patients with coronary artery disease. 34 In the Cardiovascular Health Study, which included 497 normal black subjects 465 years, the FGF23 concentrations were lower in blacks than in whites. 35 ETHNIC DIFFERENCES IN BONE MINERAL DENSITY AND FRACTURES IN HEALTHY INDIVIDUALS Black persons have substantially lower fracture rates and higher bone density than individuals of other races. Asians have lower bone density than whites, but they also have lower fracture rates Hispanic people have also lower fracture rates than whites, with similar bone density. 25 The increased bone density in blacks is already seen during childhood and adolescence. It is associated with better hip structural parameters and thicker cortices. 39 Femoral neck morphology differences between Chinese and white persons living in Australia are complex; the Chinese had a lower risk of fracture by buckling but a higher risk by bending. 40 Although serum PTH levels are consistently higher in blacks, the bone formation rate is lower. They appear to have lower skeletal response to the PTH than whites. This was also demonstrated in a study by Cosman et al., 41 who infused the biological active PTH fragment, PTH 1 34, and found that bone resorption markers showed lower responses in black subjects. Ethnic differences in the relationship between serum 25(OH)D and fractures were reported from the Women s Health Initiative. In white women, those with 25(OH)D levels 420 ng/ml had fewer fractures (odds ratio 0.82), but the reverse was seen in black women, who had more fractures (odds ratio 1.45). 42 A similar trend was seen in older adults from the NHANES survey, where a standard deviation decrease in 25(OH)D concentration was associated with an odds ratio of 1.24 for fracture in whites but 0.81 in blacks. 43 Furthermore, a randomized clinical trial of vitamin D supplementation in black women found no improvement in fracture rates compared with placebo. 44 Bone turnover markers (collagen-cross-links and osteocalcin) are lower in normal black men and women than in whites. 45,46 In a longitudinal study of perimenopausal women living in the United States, the increase in urine N-telopeptide was smaller in blacks and greater in Asians compared with whites. 47 Circulating sclerostin has been reported in one study of women aged 480 years, and it was lower in the blacks than in whites. 48 Genome-wide analysis surveys have recently been conducted to search for possible relationship between genetic variation and bone density. These have found some significant polymorphisms that associate with bone density, but still there is no explanation for the racial differences. ETHNIC DIFFERENCES IN BONE HISTOMORPHOMETRY FINDINGS AMONG HEALTHY SUBJECTS Few studies have evaluated the histomorphometric parameters of bone tissue in normal individuals of different ethnicities. Some analyzed ethnic differences in the course of age, others analyzed differences in the premenopause, 52 and others analyzed them in the premenopause and postmenopausal state Schnitzler et al. 49 studied blacks and whites in South Africa ranging in age from 21 to 83 years. The results showed 1284 Kidney International (2014) 85,

3 V Jorgetti et al.: Ethnic differences in mineral metabolism that the bone microarchitecture was better in black than in white males. In females, only bone trabeculae were thicker in black than in white individuals. With age, bone volume decreased in both genders, but the changes of microarchitecture were lower in blacks of both genders. The authors did not evaluate dynamic parameters. Schnitzler et al. 50 also studied the cortical bone from 97 blacks (49 males, 48 females) aged 22 to 80 years and from 111 whites (60 males, 51 females) aged 21 to 84 years. Fortythree subjects, 20 blacks (7 males, 13 females) aged 23 to 66 years and 23 whites (9 males, 14 females) aged 23 to 78 years, were also given tetracycline to allow measurement of the dynamic parameters of bone histomorphometry. The results showed that blacks had thicker cortical bone, less porous cortices, greater endocortical wall thickness, and fewer harvesian osteons than whites. Cortical bone deteriorated with age in both; however, the endocortical wall thickness decreased with age only in whites. The authors suggested that the preserved endocortical wall may contribute to a lower fragility rates in blacks due to greater mineral apposition and formation rates. The study of Dos Reis et al., 51 conducted in Latin America evaluated men and women aged 0 90 years. In this study, the authors assessed the influence and interaction of age, race, and gender on bone tissue. The study included blacks and whites as well as mulatto (mixed race) and individuals of Asian descent. The results showed that bone volume was influenced by race and gender. Black women and white men have greater bone volume than do white women. Microarchitecture was better in black women and worse in Asian women. Weinstein et al. 56 performed bone biopsies in 12 black and 13 white subjects who were matched for age and body weight. They found no differences in static measurements, but the bone formation rate in blacks was only 35% of that measured in whites. In another study, Parisien et al. 52 evaluated both static and dynamic bone parameters in black (aged years) and white women (aged years). Results showed similarities in volume and microarchitecture in both races. However, bone formation was again lower in black women. The authors suggested differences in the mechanism of bone formation, that is, the rate of mineral apposition in each remodeling unit was lower, leading to a longer formation period, which would allow more time for mineralization, leading to increased bone mineral density. Finally, a study from the United States that evaluated 144 black and white women in premenopause and postmenopause (aged years) showed that the effects of ethnicity are independent of age and menopause. The trabecular volume and microarchitecture parameters were larger in black women while remodeling was lower than in whites. The black women had a lower ratio of mineralizing surface to osteoid surface and therefore a prolonged bone formation period. The authors suggested that the greater bone mass reduced the need for remodeling, because there would be less microdamage Differences in osteocytes and lacunar density between blacks and whites were also evaluated. 57 In this study, the authors measured 34 bone biopsies from 34 healthy black women (aged years) and 94 white women (aged years) separately in whole trabeculae in superficial and deep bone. They concluded that blacks had more osteocytes than whites, contributing to increased bone strength. The authors speculated that osteocyte density depends more upon the age of the bone than the age of the subject. Figure 1 summarizes the results of studies that evaluated bone turnover, mineralization, and volume of white and black individuals of both genders in different age groups. ETHNIC DIFFERENCES IN VC IN PEOPLE WITHOUT KNOWN CKD Black diabetic patients have fewer arterial calcifications than their white counterparts. 11 In one study, the extent of the calcifications was inversely related to serum concentrations of Dickkopf (DKK1), which may inhibit the transformation of vascular smooth muscle cells into an osteoblastic phenotype. 58 In another study of diabetic black patients, the VCs were correlated with the serum levels of 25(OH)D, unlike white patients in whom the relationship was inverse. In these patients, serum PTH was high but not correlated to bone mineral density. Serum levels of 1,25(OH) 2 D was also high and showed a negative correlation with bone density. 59 ETHNIC DIFFERENCES IN LABORATORY MEASUREMENTS OF MINERAL METABOLISM AMONG PATIENTS WITH CKD The treatment of CKD-MBD is considered one of the most challenging tasks for nephrologists. Compared with other complications, studies show that laboratory abnormalities of mineral metabolism are associated with a percentage of death risk higher than that of anemia or low dialysis dose (17.5% vs. 11.3% and 5.1%, respectively). In an analysis of laboratory data from 40,538 hemodialysis patients, Block et al. 60 found that black patients had less hyperphosphatemia, lower serum calcium concentrations, and higher PTH values compared with white patients. In recent years, it has been shown that some ethnicityrelated variations in mineral metabolism persist when individuals develop CKD. 24,61 64 Gutiérrez et al. 24 studied 19 patients with CKD (10 blacks and 9 whites) with stage 3 4 CKD and normal serum Ca and Pi levels who received diets with known Ca and Pi content. Blacks had lower postprandial fractional urinary excretion of Ca and Pi when compared with whites. In addition, serum Ca decreased in whites but not in blacks. 24 Gupta et al. 62 were among the first authors to show that black patients receiving dialysis therapy developed more severe secondary hyperparathyroidism than did whites. The study was retrospective and was carried out in 1367 patients. Mean serum PTH levels were almost double in blacks when compared with whites. Other reports of serum PTH in black dialysis patients consistently described increased serum PTH and decreased 25(OH)D concentrations. 65 Kidney International (2014) 85,

4 V Jorgetti et al.: Ethnic differences in mineral metabolism Turnover BFR/BS (µm 3 /µm 2 /day) Mineralization OV/BV (%) Volume BV/TV (%) Premenopause Years Years Years Serum FGF23 concentrations are lower in black than in white patients with pre-dialysis CKD. 66 This bone-derived hormone has been repeatedly shown to be closely associated with increased risk of mortality and cardiovascular disease. In the Homocysteine in Kidney and End Stage Renal Disease study, there were 285 black subjects with late stages of CKD, whose average serum FGF23 levels were lower than in white subjects. Black patients with higher FGF23 had greater risk of cardiovascular events and all-cause mortality than those with lower levels. 67 In that study, the serum FGF23 of dialysis 3 Postmenopause Years Figure 1 Bone histomorphometry findings in white and black subjects without known kidney disease. Histomorphometric parameters that assessed turnover, mineralization, and volume (TMV classification), were obtained from studies of white ( ) and black ( ) individuals, women (~) and men (#), in two age brackets: years old, near the peak bone mass, and years old corresponding to postmenopausal women. Turnover was assessed only in women in premenopause and postmenopause from the values of BFR/BS (mm 3 /mm 2 /day). The values of OV/BV and BV/TV both expressed as percentages were used to evaluate mineralization and volume, respectively. Bone turnover was not different among women in both ethnic groups and in both the periods analyzed. In general, mineralization was slower in black women and bone volume was higher. The figure was constructed with results from studies by (1) Schnitzler et al. 49 (2) Han et al. 53 (3) Han et al. 54 (4) Parisien et al. 52 (5) Parfitt et al. 55 and (6) Dos Reis et al. 51 BFR/BS, bone formation rate; BV/TV, trabecular bone volume; OV/BV, osteoid volume. patients did not show differences among races. 61 However, in a larger study of 10,044 incident dialysis patients (32% black and 13% Hispanic), the serum FGF23 concentrations were significantly lower, by 22 34%, than in the white patients. Mortality during the first year of dialysis was substantially lower in black and Hispanic patients (odds ratio 0.5 and 0.4). 66 ETHNIC DIFFERENCES IN THE BONE AMONG PATIENTS WITH CKD White dialysis patients have more hospitalizations for fractures than patients of other races. 60 In a large clinical trial of cinacalcet, black subjects had a significantly longer time to fracture (hazard ratio 0.48 compared with whites). 68 In a cohort study of 101,039 patients on a renal transplant waiting list, which included 29,183 black patients, the risk of a hip fracture was 62% lower in black patients. 69 Bone density is also higher in black than in white patients with CKD. One study found that black patients had a mean of 1.15 s.ds. greater bone density at the hip than whites. 70 Although PTH levels are higher in blacks, they do not necessarily develop a more severe bone disease. Sawaya et al. 63 evaluated bone biopsies in 76 patients receiving dialysis treatment (48 whites and 28 blacks) who did not have evidence of aluminum overload, negative aluminum staining in bone, and had not undergone parathyroidectomy. The authors found no racial differences in bone volume. Low bone turnover was seen in 64% of white and 53% of black patients, and serum PTH and alkaline phosphatase levels were higher in blacks irrespective of the type of bone remodeling. The serum PTH showed significant correlations to bone formation in white patients but not in black patients. In a recent study, Malluche et al. 71 revised biopsies from a bank of bone biopsies performed between 2003 and Of these patients, 87 were black and 543 were white. The authors classified the results in accordance with the newly recommended histological classification system for renal osteodystrophy: 18 Turnover (T) Mineralization (M) Volume (V), in addition to Architecture (A) both in the cancellous bone and in cortical bone. Low bone turnover was seen in 62% of white patients but only in 32% of black patients. Only 3% of all patients showed mineralization defect. As for the volume, white patients had approximately the same proportion of low, normal, and high bone volume, whereas black patients had predominantly high bone volume. Black patients had thicker cortical bone, but with higher porosity. Caucasian patients, however, had similar low or normal cortical thickness but normal and high porosity. Black patients had higher serum PTH levels, but for the same PTH level, they had lower bone turnover, suggesting lower skeletal response to PTH. Shin et al. 72 carried out bone biopsies in 58 Korean predialysis patients to investigate the distribution of different types of renal osteodystrophy and possible ethnic differences between Asians and whites. The turnover was different from that of end-stage kidney disease patients in Western 1286 Kidney International (2014) 85,

5 V Jorgetti et al.: Ethnic differences in mineral metabolism Table 1 Main differences in bone and mineral metabolism parameters in black individuals compared with white individuals Normal or early CKD Late stage CKD, including dialysis Disease/mortality More rapid progression Better survival Serum calcium Similar Lower Serum phosphate Similar Lower Intestinal calcium More efficient absorption Urine calcium Lower excretion Serum 25(OH)D Lower Lower Serum 1,25(OH) 2 D Higher Serum PTH Higher Higher Serum FGF23 Similar or lower Lower Fracture rates Lower Lower Bone mineral density Higher Higher Bone formation rates Lower Higher Bone volume Higher or similar Higher Bone response to PTH Less resorption Less resorption Fracture association with vitamin D level Fewer fractures with low vitamin D Vascular calcifications Fewer in diabetic patients Fewer or similar Hospitalization for cardiovascular disease Higher (or similar with equal access to care) Fewer Abbreviations: CKD, chronic kidney disease; FGF23, fibroblast growth factor 23; PTH, parathyroid hormone. countries, with fewer cases of adynamic bone disease (24.6%) or severe osteitis fibrosis (8.6%). Mineralization abnormalities were seen in 22.4%. The average bone volume per tissue volume was between 30 and 40% in all the categories of renal osteodystrophy, except the adynamic bone disease in which it was 23%. ETHNIC DIFFERENCES IN CARDIOVASCULAR CALCIFICATIONS AMONG PATIENTS WITH CKD Cardiovascular disease is the leading cause of death in patients with CKD. Its etiology is multifactorial and VC is considered to be one of the major contributory factors. Black individuals have better survival rates than whites, especially at the start of dialysis. This survival advantage is attributed to a lower prevalence of VC and cardiovascular disease. 12 In a descriptive cohort study (Multi-Ethnic Study of Atherosclerosis) the authors examined the incidence and progression of coronary artery calcification (CAC) in a multiethnic population with predominantly stage 3 CKD. The CAC score was measured at baseline and again approximately 1.6 or 3.2 years later. CAC prevalence at baseline was 66%, and its adjusted prevalence was 24% lower in blacks as compared with whites. Incident CAC developed at a rate of 14.8% per year in men and 6.1% per year in women, similar by ethnicity and sex, and associated with the presence of diabetes. 73 Similar results were obtained in a study carried out in South African patients. 74 Bellasi et al. 75 evaluated dialysis patients with a high prevalence of diabetes and long dialysis vintage. They found no differences in the prevalence of VC between the two ethnic groups. White hemodialysis patients were reported to have more hospitalizations for cardiovascular disease and for vascular access problems than patients of other races. 60 Table 1 summarizes the main differences in bone and mineral parameters between black and white individuals with normal kidney function or early stage CKD as compared with late stage CKD patients. SUMMARY Ethnicity has an important role in all aspects of mineral metabolism, both in healthy persons and in patients with chronic kidney disease. Black persons have a significant advantage in this respect: they have stronger bones and less cardiovascular calcification. Black patients receiving dialysis therapy have fewer hospitalizations for cardiovascular disease, fewer fractures, and lower mortality rates. The limited studies enrolling both Asian and non-asian patients suggest differences in bone parameters and fracture rates. Currently, there is still no recognized molecular basis for these ethnic differences in mineral and skeletal metabolism, highlighting a serious gap in our understanding of bone and vascular diseases, our lack of knowledge of the optimal treatment according to ethnic background, and the need for further research into this area. Note added in proof: A recent article found that Vitamin D-binding protein was lower in black Americans, which explains much of the difference in vitamin D levels between black and white individuals. 76 DISCLOSURE VJ is an advisor/consultant for Sanofi-Genzyme, Abbott, and Amgen, and a lecturer for Sanofi-Genzyme, Abbott, and Amgen. All the other authors declared no competing interests. ACKNOWLEDGMENTS We acknowledge the technical assistance provided by Wagner Vasques Dominguez and also in editing of the figure. REFERENCES 1. Kanis JA, Odén A, McCloskey EV et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23: Looker A, Melton LJ 3rd, Borrud LG et al. Changes in femur neck bone density in US adults between and : demographic patterns and possible determinants. Osteoporos Int 2012; 23: Bachrach LK, Hastie T, Wang MC et al. Bone mineral acquisition in healthy Asian, Hispanic, Black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab 1999; 84: Jackman L, Millane SS, Martin BR et al. Calcium retention in relation to calcium intake and post menarcheal age in adolescent females. Am J Clin Nutr 1997; 66: Abrams SA, O Brien KO, Liang LK et al. Differences in calcium absorption and kinetics between black and white girls aged 5 16 years. J Bone Miner Res 1995; 10: Braun M, Palacios C, Wigertz K et al. Racial differences in skeletal calcium retention in adolescent girls with varied controlled calcium intakes. Am J Clin Nutr 2007; 85: Zadshir A, Tareen N, Pan D et al. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005; 15: Kidney International (2014) 85,

6 V Jorgetti et al.: Ethnic differences in mineral metabolism 8. Clemens TL, Adams JS, Henderson SL et al. Increased skin pigment reduces the capacity of skin to synthesize vitamin D3. Lancet 1982; 1: Nesby-O Dell S, Scanlon KS, Cogswell ME et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, Am J Clin Nutr 2002; 76: Fuleihan GE, Gundberg CM, Gleason R et al. Racial differences in parathyroid hormone dynamics. JClinEndocrinolMetab1994; 79: Freedman BI, Register TC. Effect of race and genetics on vitamin D metabolism, bone and vascular health. Nat Rev Nephrol 2012; 8: US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, Derose SF, Rutkowski MP, Crooks PW et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis 2013; 62: Kovesdy CP, Quarles LD, Lott EH et al. Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix. Am J Kidney Dis 2013; 62: Kritchevsky SB, Tooze JA, Neiberg RH et al. 25-Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: the health ABC study. J Clin Endocrinol Metab 2012; 97: Kalantar-Zadeh K, Golan E, Shohat T et al. Survival disparities within American and Israeli dialysis populations: learning from similarities and distinctions across race and ethnicity. Semin Dial 2010; 23: Wolf M, Betancourt J, Chang Y et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: Broadus AE. Physiological functions of calcium, magnesium, and phosphorus and mineral ion balance. In: Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism (ed. Favus MJ) Raven Press: New York, USA, pp Daniels ED, Pettifor JM, Schnitzler CM et al. Differences in mineral homeostasis, volumetric bone mass and femoral neck axis length in black and white South African women. Osteoporosis Int 1997; 7: Na T, Zhang W, Jiang Y et al. The A563T variation of the renal epithelial calcium channel TRPV5 among African Americans enhances calcium influx. Am J Physiol Renal Physiol 2009; 296: F1042 F Jung J, Foroud TM, Eckert GJ et al. Association of the calcium-sensing receptor gene with blood pressure and urinary calcium in African- Americans. J Clin Endocrinol Metab 2009; 94: Arunabh S, Feuerman M, Ruimei MA et al. Total body phosphorus in healthy women and ethnic variations. Metabolism 2002; 51: Gutiérrez OM, Isakova T, Smith K et al. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant 2010; 25: Gutiérrez OM, Farwell WR, Kermah D et al. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 2011; 22: Jablonski NG, Chaplin G. Human skin pigmentation, migration and disease susceptibility. Philos Trans R Soc Lond B Biol Sci 2012; 367: Gallagher JC, Peacock M, Yalamanchili V et al. Effects of vitamin D supplementation in older African American women. J Clin Endocrinol Metab 2009; 93: Bell NH, Greene A, Epstein S et al. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985; 76: Bosworth C, Sachs MC, Duprez D et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol 2013; 79: Nakamura K, Nashimoto M, Hori Y et al. Serum parathyroid hormone in healthy Japanese women in relation to serum 25-hydroxyvitamin D. Int J Vitam Nutr Res 2000; 70: Ghandur-Mnaymneh L, Cassady J, Hajianpour MA et al. The parathyroid gland in health and disease. Am J Pathol 1986; 125: Dalal M, Sun K, Cappola AR et al. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011; 165: Ix JH, Chonchol M, Laughlin GA et al. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J kidney Dis 2011; 58: Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: Ix JH, Katz R, Kestenbaum BR et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: Xu L, Lu A, Zhao X et al. Very low rates of hip fracture in Beijing, People s Republic of China: the Beijing Osteoporosis Project. Am J Epidemiol 1996; 144: Lau EM, Lee JK, Suriwongpaisal P et al. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 2001; 12: Ross PD, Norimatsu H, Davis JW et al. A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians. Am J Epidemiol 1991; 133: Norris SA, Nelson DA. Ethnic differences in bone acquisition.. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (ed. Rosen CJ) John Wiley & Sons: New Jersey, USA, pp Wang XF, Duan Y, Beck TJ et al. Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 2005; 36: Cosman E, Morgan DC, Nieves JW et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: Cauley JA, Danielson ME, Boudreau R et al. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women s Health Initiative (WHI). J Bone Miner Res 2011; 26: Looker AC. Serum 25-hydroxyvitamin D and risk of major osteoporotic fractures in older U.S. adults. J Bone Miner Res 2013; 28: Aloia JE, Talwar SA, Pollack S et al. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 2005; 165: Leder BZ, Araujo AB, Travison TG et al. Racial and ethnic differences in bone turnover markers in men. J Clin Endoclin Metab 2007; 92: Sowers M, Derby C, Jannausch ML et al. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endoclin Metab 2003; 88: Sowers MR, Zheng H, Greendale GA et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab 2013; 98: Thorson S, Prasad T, Sheu Y et al. Sclerostin and bone strength in women in their 10 th decade of life. J Bone Miner Res 2013; 28: Schnitzler CM, Pettifor JM, Mesquita JM et al. Histomorphometry of iliac crest in 346 normal black and white South African adults. Bone Miner 1990; 10: Schnitzler CM, Mesquita JM. Cortical bone histomorphometry of the iliac crest in normal black and white South Africans adults. Calcif Tissue Int 2006; 79: Dos Reis LM, Batalha JR, Muñoz DR et al. Brazilian normal static bone histomorphometry: effects of age, sex and race. J Bone Miner Metab 2007; 25: Parisien M, Cosman F, Morgan D et al. Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res 1997; 12: Han ZH, Palnitkar S, Rao DS et al. Effect of ethnicity and age or menopause on the structure and geometry of iliac bone. J Bone Miner Res 1996; 11: Han ZH, Palnitkar S, Rao DS et al. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 1997; 12: Parfitt AM, Han ZH, Palnitkar S et al. Effects of ethnicity and age or menopause on osteoblast function, bone mineralization, and osteoid accumulation in iliac bone. J Bone Miner Res 1997; 12: Weinstein RS, Bell NH. Diminished rates of bone formation in normal black adults. N Engl J Med 1988; 319: Qiu S, Rao DS, Palnitkar S et al. Differences in osteocyte and lacunar density between black and white American women. Bone 2006; 38: Register TC, Hruska KA, Divers J et al. Plasma Dickkopft1 (DKK1) concentrations negatively associate with atherosclerotic clacified plaque 1288 Kidney International (2014) 85,

7 V Jorgetti et al.: Ethnic differences in mineral metabolism in African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2013; 98: E60 E Freedman BI, Wagenknecht LE, Hairston KG et al. Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 2010; 95: Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: Jovanovich A, Chonchol M, Cheung AK et al. Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: Gupta A, Kallenbach LR, Zasuwa G et al. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000; 11: Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and caucasian patients with end-stage renal disease. Kidney Int 2003; 64: Ennis J, Worcester EM, Coe F et al. Contribution of calcium, phosphorus, and 25-hydroxyvitamin D to the excessive severity of secondary hyperparathyroidism in African Americans with CKD. Nephrol Dial Transplant 2012; 27: Gutiérrez OM, Isakova T, Andress DL et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008; 73: Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: EVOLVE Trial Investigators, Chertow GM, Block GA et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288: Stehman-Breen CO, Sherrard D, Walker A et al. Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 1999; 33: Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26: Shin SK, Kim DH, Kim HS et al. Renal osteodystrophy in pre-dialysis patients: ethnic difference? Perit Dial Int 1999; 19: S402 S Kestenbaum BR, Adeney KL, de Boer IH et al. Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. Kidney Int 2009; 76: Freercks R, Swanepoel C, Carrara H et al. Vascular calcification in South African dialysis patients: ethnic variation, prevalence, detection and haemodynamic correlates. Nephrology 2012; 17: Bellasi A, Veledar E, Ferramosca E et al. Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile. Atherosclerosis 2008; 197: Powe CE, Evans MK, Wenger J et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: Kidney International (2014) 85,

Metabolic Bone Disease Related to Chronic Kidney Disease

Metabolic Bone Disease Related to Chronic Kidney Disease Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab

More information

Kobe University Repository : Kernel

Kobe University Repository : Kernel Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms

More information

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School

More information

The Skeletal Response to Aging: There s No Bones About It!

The Skeletal Response to Aging: There s No Bones About It! The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium

More information

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker

More information

Bone Disorders in CKD

Bone Disorders in CKD Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis

More information

Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease

Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA

More information

Should cinacalcet be used in patients who are not on dialysis?

Should cinacalcet be used in patients who are not on dialysis? Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.

More information

CKD-MBD CKD mineral bone disorder

CKD-MBD CKD mineral bone disorder CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

The hart and bone in concert

The hart and bone in concert The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel

More information

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019

Persistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019 Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal

More information

Bone Disease after Kidney Transplantation

Bone Disease after Kidney Transplantation Bone Disease after Kidney Transplantation BTS March 2018 Dr Arif Khwaja PhD, FRCP Sheffield Kidney Institute Clinical case 47 year old female FSGS DBD 2007 egfr 25mls/min. Sirolimus, Azathioprine and prednisolone

More information

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum

More information

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker

More information

Setting the standard

Setting the standard SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics

More information

CAD in Chronic Kidney Disease. Kuang-Te Wang

CAD in Chronic Kidney Disease. Kuang-Te Wang CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,

More information

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes ..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol

More information

Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients

Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology

More information

Hyperphosphatemia is associated with a

Hyperphosphatemia is associated with a TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular

More information

chapter 1 & 2009 KDIGO

chapter 1 & 2009 KDIGO http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3

More information

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse

More information

Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations

Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations Osteoporosis and Chronic Kidney Disease: Diagnosis and Treatment Recommendations Nancy E. Lane, MD Director, Center for Musculoskeletal Health Endowed Professor of Medicine and Rheumatology University

More information

Management of mineral and bone disorders in renal transplant recipients

Management of mineral and bone disorders in renal transplant recipients Nephrology 22, Suppl. 2 (2017) 65 69 Management of mineral and bone disorders in renal transplant recipients MATTHEW J DAMASIEWICZ 1,3 and PETER R EBELING 2,3,4 Departments of 1 Nephrology, and 2 Endocrinology,

More information

Therapeutic golas in the treatment of CKD-MBD

Therapeutic golas in the treatment of CKD-MBD Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral

More information

White Rose Research Online URL for this paper: Version: Accepted Version

White Rose Research Online URL for this paper:   Version: Accepted Version This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this

More information

2017 KDIGO Guidelines Update

2017 KDIGO Guidelines Update 2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation

More information

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular

More information

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD

More information

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among

More information

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD

Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass

More information

Cinacalcet treatment in advanced CKD - is it justified?

Cinacalcet treatment in advanced CKD - is it justified? Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to

More information

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010 Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,

More information

Nuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases

Nuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases tap_919 9..13 Therapeutic Apheresis and Dialysis 15(Supplement 1):9 13 doi: 1.1111/j.1744-9987.211.919.x Therapeutic Apheresis and Dialysis 211 International Society for Apheresis Nuclear Chromatin-concentrated

More information

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009. http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording

More information

EPIDEMIOLOGICAL DATA FROM multiple U.S. populations

EPIDEMIOLOGICAL DATA FROM multiple U.S. populations JOURNAL OF BONE AND MINERAL RESEARCH Volume 22, Supplement 2, 2007 doi: 10.1359/JBMR.07S220 2007 American Society for Bone and Mineral Research Vitamin D Economy in Blacks Felicia Cosman, 1,2 Jeri Nieves,

More information

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea

More information

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:

More information

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How

More information

The Low Blood Level of 25-Hydroxy Vitamin D in African American Women: Is It Clinically Significant?

The Low Blood Level of 25-Hydroxy Vitamin D in African American Women: Is It Clinically Significant? Cronicon OPEN ACCESS The Low Blood Level of 25-Hydroxy Vitamin D in African American Women: Is It Clinically Significant? NUTRITION Review Article Fafa Huberta Koudoro 1#, Ria S Roberts 1#, Mark S Elliott

More information

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)

CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,

More information

Endocrine Regulation of Calcium and Phosphate Metabolism

Endocrine Regulation of Calcium and Phosphate Metabolism Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn

More information

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11): Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,

More information

Functions of the Skeletal System. Chapter 6: Osseous Tissue and Bone Structure. Classification of Bones. Bone Shapes

Functions of the Skeletal System. Chapter 6: Osseous Tissue and Bone Structure. Classification of Bones. Bone Shapes Chapter 6: Osseous Tissue and Bone Structure Functions of the Skeletal System 1. Support 2. Storage of minerals (calcium) 3. Storage of lipids (yellow marrow) 4. Blood cell production (red marrow) 5. Protection

More information

Sensipar. Sensipar (cinacalcet) Description

Sensipar. Sensipar (cinacalcet) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)

More information

FGF23 in CKD and ESRD Regulator of phosphorus balance, or much more than that?

FGF23 in CKD and ESRD Regulator of phosphorus balance, or much more than that? FGF23 in CKD and ESRD Regulator of phosphorus balance, or much more than that? Csaba P Kovesdy MD University of Tennessee Health Science Center Memphis, TN USA Learning Objectives Review the pathogenesis

More information

BONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis

BONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease

More information

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals

More information

Guidelines and new evidence on CKD - MBD treatment

Guidelines and new evidence on CKD - MBD treatment Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

PART FOUR. Metabolism and Nutrition

PART FOUR. Metabolism and Nutrition PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy

More information

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2013 September 01.

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2013 September 01. Choices in kidney transplantation in type 1 diabetes: Are there skeletal benefits of the endocrine pancreas? Julia J. Scialla, MD, MHS Division of Nephrology and Hypertension, Department of Medicine, University

More information

Elecsys bone marker panel. Optimal patient management starts in the laboratory

Elecsys bone marker panel. Optimal patient management starts in the laboratory bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic

More information

The Role of the Laboratory in Metabolic Bone Disease

The Role of the Laboratory in Metabolic Bone Disease The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology

More information

Chapter 39: Exercise prescription in those with osteoporosis

Chapter 39: Exercise prescription in those with osteoporosis Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:

More information

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement

More information

RENAL OSTEODYSTROPHY continues to

RENAL OSTEODYSTROPHY continues to Variant of Adynamic Bone Disease in Hemodialysis Patients: Fact or Fiction? Lillian A. Rocha, MD, Andrea Higa, MD, Fellype C. Barreto, MD, Luciene M. dos Reis, PhD, Vanda Jorgetti, MD, PhD, Sérgio A. Draibe,

More information

Normal kidneys filter large amounts of organic

Normal kidneys filter large amounts of organic ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Treatment Options for Chronic Kidney

Treatment Options for Chronic Kidney Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition

More information

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

Introduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a

Introduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença

More information

The role of calcimimetics in chronic kidney disease

The role of calcimimetics in chronic kidney disease http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,

More information

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation

More information

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department

More information

A Case of Incomplete Atypical Femoral Fracture with Histomorphometrical Evidence of Osteomalacia

A Case of Incomplete Atypical Femoral Fracture with Histomorphometrical Evidence of Osteomalacia 2015 69 1 59 63 A Case of Incomplete Atypical Femoral Fracture with Histomorphometrical Evidence of Osteomalacia a* b c c c b a b c 60 69 1 Magnetic resonance imaging (MRI) of the bilateral femurs. Right

More information

BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE

BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE Andreas Panagopoulos, MD, PhD Assistant Professor in Orthopaedics University Hospital of Patras, Orthopaedic Clinic Objectives Bone structure and

More information

FOCUS ON CARDIOVASCULAR DISEASE

FOCUS ON CARDIOVASCULAR DISEASE The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.

More information

KDOQI COMMENTARY VOL 55, NO 5, MAY 2010

KDOQI COMMENTARY VOL 55, NO 5, MAY 2010 VOL 55, NO 5, MAY 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD Mineral and Bone Disorder (CKD-MBD) Katrin

More information

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012 Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco

More information

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral

More information

OPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura

OPEN.  Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance

More information

Download slides:

Download slides: Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division

More information

A Novel Murine Model Of Adynamic Bone Disease (ABD)

A Novel Murine Model Of Adynamic Bone Disease (ABD) A Novel Murine Model Of Adynamic Bone Disease (ABD) Adeline H. Ng 1,2, Thomas L. Willett, PhD 2,1, Benjamin A. Alman 3,1, Marc D. Grynpas 1,2. 1 University of Toronto, Toronto, ON, Canada, 2 Samuel Lunenfeld

More information

Improvement of adynamic bone disease after renal transplantation

Improvement of adynamic bone disease after renal transplantation Brazilian Journal of Medical and Biological Research (2006) 39: 31-41 Adynamic bone disease after transplantation ISSN 0100-879X 31 Improvement of adynamic bone disease after renal transplantation K.A.

More information

Management of CKD. Goce Spasovski, R. Macedonia

Management of CKD. Goce Spasovski, R. Macedonia Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD

More information

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Vitamin D and osteoporosis in chronic kidney disease

Vitamin D and osteoporosis in chronic kidney disease DOI 10.1007/s40620-017-0430-x REVIEW Vitamin D and osteoporosis in chronic kidney disease Paul Lips 1 David Goldsmith 2 Renate de Jongh 1 Received: 9 May 2017 / Accepted: 4 August 2017 / Published online:

More information

Chapter 6: SKELETAL SYSTEM

Chapter 6: SKELETAL SYSTEM Chapter 6: SKELETAL SYSTEM I. FUNCTIONS A. Support B. Protection C. Movement D. Mineral storage E. Lipid storage (Fig. 6.8b) F. Blood cell production (Fig. 6.4) II. COMPONENTS A. Cartilage 1. Hyaline 2.

More information

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1 Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,

More information

Persistent knee pain in a patient with systemic lupus erythematosus

Persistent knee pain in a patient with systemic lupus erythematosus CASE REPORT Port J Nephrol Hypert 2018; 32(4): 374-378 Advance Access publication 31 October 2018 Persistent knee pain in a patient with systemic lupus erythematosus Miguel Bigotte Vieira 1, *, Joana Monteiro

More information

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (

More information

Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist

Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency. Spyridon Karras MD, Phd Endocrinologist Hellenic Endocrine Society position statement: Clinical management of Vitamin D Deficiency Spyridon Karras MD, Phd Endocrinologist Pregnancy We recommend a minimum intake of 600 international units of

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

HAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013

HAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013 HIV correlated pathologies and other infections HIV & BONE METABOLISM Bologna, April 5 th, 2013 Morning Session: Davide Gibellini, Fabio Vescini, Paolo Bonfanti, Stefano Mora, Antonio Di Biagio, Tiziana

More information

An Introduction to the Skeletal System Skeletal system includes Bones of the skeleton Cartilages, ligaments, and connective tissues

An Introduction to the Skeletal System Skeletal system includes Bones of the skeleton Cartilages, ligaments, and connective tissues An Introduction to the Skeletal System Skeletal system includes Bones of the skeleton Cartilages, ligaments, and connective tissues Functions of the Skeletal System Support Storage of minerals (calcium)

More information

Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012.

Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012. Current Concepts in the Evaluation and Management of Abnormal Parathyroid Hormone (PTH) Levels Shireen Fatemi, M.D. April, 2012 Disclosures I have no financial relationships with commercial interests,

More information

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2 Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and

More information

PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL

PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide

More information

Posttransplant Bone Disease. Budapest 2007

Posttransplant Bone Disease. Budapest 2007 Posttransplant Bone Disease Budapest 2007 Post-transplant bone disease 7 10 % of kidney transplanted patients develope a fracture. The risk is higher in postmenopausal female transplanted patients. Diabetic,

More information

Recent advances in the noninvasive diagnosis of renal osteodystrophy

Recent advances in the noninvasive diagnosis of renal osteodystrophy http://www.kidney-international.org & 2013 International Society of Nephrology Recent advances in the noninvasive diagnosis of renal osteodystrophy Ranjani N. Moorthi 1 and Sharon M. Moe 1,2 1 Department

More information

Chronic kidney disease (CKD) and the

Chronic kidney disease (CKD) and the BONE COPLICATIONS AND CALCIFICATION OF SOFT TISSUES IN CHRONIC KIDNEY DISEASE * John P. iddleton, D, and Hartmut H. alluche, D, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality

More information

DM and Osteoporosis. Why is it important?

DM and Osteoporosis. Why is it important? DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM

More information